BridgeMD
New treatment option for Locally Advanced Resectable Rectal Cancer
Official title A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
ClinicalTrials.gov ID: NCT07454720
What this study is testing
What is Adebrelimab in combination with SHR-8068 and chemotherapy?
Adebrelimab in combination with SHR-8068 and chemotherapy is an investigational medicine, being studied as a potential treatment for locally advanced resectable rectal cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- people must voluntarily agree to participate in the trial and sign a written informed consent form.
- Male or female ≥ 18 years old and ≤75 years old.
- ECOG performance status of 0-1.
- An assessment of resectable locally advanced rectal.
- Has not received any anti-tumor treatment for rectal cancer.
You likely can't join if
- Patients with rectal cancer who have experienced local recurrence after previous treatment.
- Patients with concurrent colon tumors.
- Patients with initially unresectable colorectal cancer as evaluated by researchers or those whose condition is determined by researchers to be...
- Clinical or imaging examinations suggest the presence of intestinal obstruction or perforation, or those assessed by researchers as having a...
- With distant metastases.
- Imaging examination of rectal cancer indicated positive lateral lymph nodes.
See the full eligibility criteria
- people must voluntarily agree to participate in the trial and sign a written informed consent form.
- Male or female ≥ 18 years old and ≤75 years old.
- ECOG performance status of 0-1.
- An assessment of resectable locally advanced rectal.
- Has not received any anti-tumor treatment for rectal cancer.
- With a life expectancy of ≥2 years.
- Male participants whose partners are fertile women and fertile female participants must take effective contraceptive measures together with their partners from the time of signing the informed consent form until 6...
- Patients with rectal cancer who have experienced local recurrence after previous treatment.
- Patients with concurrent colon tumors.
- Patients with initially unresectable colorectal cancer as evaluated by researchers or those whose condition is determined by researchers to be intolerant to surgery.
- Clinical or imaging examinations suggest the presence of intestinal obstruction or perforation, or those assessed by researchers as having a relatively high risk of perforation or bleeding.
- With distant metastases.
- Imaging examination of rectal cancer indicated positive lateral lymph nodes.
- Having received surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. for tumors.
- Female participants who are pregnant, breastfeeding or planning to become pregnant during the study period.
- There are uncontrollable mental illnesses and other circumstances known to affect the completion of the research procedures, such as alcohol abuse, drug abuse or drug abuse, and criminal detention.
- Any other factors that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate as judged by investigators.
The study team makes the final eligibility decision.
Where it's taking place
- Wuhan, Hubei, China
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wuhan, Hubei, China; Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.